Latest News and Press Releases

Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate...

- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with...

Charlottesville, Virginia, April 22, 2026 (GLOBE NEWSWIRE) -- Luminoah, a medical technology company focused on modernizing enteral nutrition, today announced it has received U.S. Food and Drug...

马萨诸塞州沃尔瑟姆, April 22, 2026 (GLOBE NEWSWIRE) -- 维泰瑞隆是一家处于临床阶段的全球化生物科技公司，致力于开发针对神经退行性疾病、炎症与免疫性疾病、代谢性疾病和罕见病的变革性疗法。公司今日宣布，其摘要已入选美国临床肿瘤学会（ASCO）年会并将在海报展示环节进行展示。本届年会将于5月29日至6月2日在伊利诺伊州芝加哥市举办。 展示详情如下： ...

麻薩諸塞州 沃爾瑟姆, April 22, 2026 (GLOBE NEWSWIRE) -- 維泰瑞隆是一家處於臨床階段的全球化生物科技公司，致力於開發針對神經退行性疾病、炎症與免疫性疾病、代謝性疾病和罕見病的變革性療法。公司今日宣佈，其摘要已入選美國臨床腫瘤學會（ASCO）年會並將在海報展示環節進行展示。本屆年會將於5月29日至6月2日在伊利諾州芝加哥市舉辦。 展示詳情如下： ...

New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy Plinabulin’s...

Blue Mountain acquisition of Compucal acquisition Expands Global Footprint and Strengthens Leadership Across Life Sciences Manufacturing

EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points...

STATE COLLEGE, Pennsylvania, und CORK, Irland, April 22, 2026 (GLOBE NEWSWIRE) -- Blue Mountain, ein führender Anbieter von GMP-konformer Enterprise-Asset-Management-Software (EAM) für die...

STATE COLLEGE, Pennsylvanie et CORK, Irlande, 22 avr. 2026 (GLOBE NEWSWIRE) -- Blue Mountain, leader des logiciels de gestion des actifs d’entreprise (EAM) conformes aux bonnes pratiques de...